Back to Business
Business
6 August 2026
Eli Lilly stock soars on strong demand for weight-loss drugs
Eli Lilly raised its 2026 sales forecast as its GLP-1 drugs outperformed expectations in Q2.
About this report
Downunder Voices provides an independently written summary and community perspective based on information published by the original source. The original publisher remains responsible for its reporting.
Join our community
Follow Downunder Voices
Join thousands of readers following news and community stories from Australia, New Zealand and the Pacific.
